Core Viewpoint - The article emphasizes the investment potential in the Hong Kong pharmaceutical sector, particularly focusing on "China Innovation Drug 3.0," which signifies a shift from a follower to a leader in the global pharmaceutical landscape. The sector is expected to thrive in 2025, driven by high elasticity and significant narratives, making it a prime investment opportunity [1]. Group 1: Investment Highlights - The Hong Kong pharmaceutical sector has shown remarkable performance, with the Hang Seng Innovation Drug Index rising approximately 165% from its low in April last year to August 11 this year, significantly outperforming the Hang Seng Index, which increased by 58% [1]. - The article identifies four key investment themes that combine "high growth stories" with "low drawdown experiences," making the sector attractive for investors [3]. Group 2: Key Drivers - **Era Beta: Innovation Drug 3.0**: Over the past decade, China's pharmaceutical industry has transitioned from a "follower" role to a "leader," with a license-out transaction amount of $51.9 billion in 2024, reflecting a compound annual growth rate of 125%. China has become the second-largest BD output country globally, following the U.S. [4][6]. - **Catalytic Calendar**: The article highlights upcoming events such as the WCLC and ESMO conferences, which are expected to showcase promising data from domestic innovative drugs, potentially driving further interest and investment in the sector [8][9]. - **Capital Market Resonance**: There has been a significant inflow of capital into the Hong Kong pharmaceutical sector, with foreign investments increasing, as evidenced by BlackRock's acquisition of shares in Innovent Biologics [10]. - **Valuation Safety Net**: As of August 8, the PE ratio for the Hang Seng Healthcare Index and the Hong Kong Stock Connect Healthcare Index is around 17x, which is still 60% lower than the peak of 43x in 2021, indicating potential for further growth [11][12]. Group 3: Investment Strategy - The South China Hong Kong Pharmaceutical Industry Mixed Fund (QDII) has demonstrated a benchmark performance increase of approximately 76.7% as of August 5 this year, successfully combining high elasticity and low drawdown in its net value curve [15]. - The fund's investment strategy focuses on high-growth innovative drug sectors, emphasizing a balanced approach that includes both aggressive and defensive positions to manage volatility effectively [17].

Group 1 - The core viewpoint of the news is the increasing enthusiasm among fund companies to apply for QDII (Qualified Domestic Institutional Investor) business, driven by the strong performance of QDII products over the past three years [1][2] - As of August 1, 2023, Xinyin Fund has officially applied for QDII business qualifications, becoming the fourth fund company to do so this year, following Xinyuan Fund, Minsheng Jia Yin Fund, and Guolian An Fund [1] - The total scale of QDII funds reached approximately 680 billion yuan by the end of June 2023, more than double the scale at the end of 2022, indicating a significant growth trend [2] Group 2 - The average net value growth of QDII funds has shown a positive trend, with annual average net value increases of 6%, 12%, and 16% in recent years, highlighting a consistent upward trajectory [1][2] - The most profitable QDII fund this year is the Huatai-PB Hong Kong Advantage Selected Mixed Fund, which has achieved a net value increase of 144% [1] - QDII-ETF products have seen substantial inflows, with over 16 billion units net subscribed since July, contributing to a total scale of 364.5 billion yuan [2]